Breaking News

ProBioGen, ImmunOs Therapeutics Extend Clinical Mfg. Pact

Will continue large-scale manufacturing of clinical material for ImmunOs lead program for the treatment of cancer.

ProBioGen and ImmunOs Therapeutics have extended their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs’ biologic. “We at ImmunOs are very satisfied with the work done by ProBioGen,” said Jeff Abbey, chief operating officer of ImmunOs Therapeutics. “We highly ap...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters